Prostate-specific antigen and other serum and urine markers in prostate cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 99-112

  Stephan, Carsten ^a,b   Ralla, Bernhard ^a   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

Biomarkers; PCA3; Prostate cancer; Prostate health index; PSA; TMPRSS2

Indexed keywords

ANDROGEN; CALGRANULIN A; CALGRANULIN B; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; KALLIKREIN; KALLIKREIN 2; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; SARCOSINE; SERUM MARKER; SPONDIN 2; TUMOR MARKER; UNCLASSIFIED DRUG; UNTRANSLATED RNA; URINE MARKER; BIOLOGICAL MARKER; MEMBRANE PROTEIN; PROTEIN PCA3; PROTEIN TMPRSS2;

AMINO ACID BLOOD LEVEL; AMINO ACID URINE LEVEL; ANTIGEN DETECTION; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; FUSION GENE; GENE CONTROL; HUMAN; KALLIKREIN BLOOD LEVEL; KALLIKREIN URINE LEVEL; MULTIGENE FAMILY; ONCOGENE; ONCOGENE ERG; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE HYPERTROPHY; PROTEIN FAMILY; REVIEW; SARCOSINE BLOOD LEVEL; SARCOSINE URINE LEVEL; SENSITIVITY AND SPECIFICITY; TMPRSS2 GENE; TRANSCRIPTION FACTOR GENE; TUMOR GENE; URINALYSIS; ANTIGEN SPECIFICITY; CANCER RISK; COMPUTER PROGRAM; GENE; NONHUMAN; PCA3 GENE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN URINE LEVEL;

BIOMARKERS; PCA3; PROSTATE CANCER; PROSTATE HEALTH INDEX; PSA; TMPRSS2;

ANIMALS; HUMANS; KALLIKREINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899840486     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.04.001     Document Type: Review

References (208)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
3. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49:1374-1403.
4. Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O., Bray F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61:1079-1092.
5. Papsidero L.D., Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980, 40:2428-2432.
6. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J. Urol. 1999, 162:293-306.
7. Lilja H., Oldbring J., Rannevik G., Laurell C.B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J. Clin. Invest. 1987, 80:281-285.
8. Stenman U.H. Prostate-specific antigen, clinical use and staging: an overview. Br. J. Urol. 1997, 79(Suppl. 1):53-60.
9. Hughes E., Kilmer G., Li Y., Valluru B., Brown J., Colclough G., Geathers S., Roberts H., Elam-Evans L., Balluz L. Surveillance for certain health behaviors among states and selected local areas - United States, 2008. MMWR Surveill. Summ. 2010, 59:1-221.
10. Aus G., Damber J.E., Khatami A., Lilja H., Stranne J., Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch. Intern. Med. 2005, 165:1857-1861.
11. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., Coltman C.A. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0ng per milliliter. N. Engl. J. Med. 2004, 350:2239-2246.
12. Schröder F.H., van der Cruijsen-Koeter I., De Koning H.J., Vis A.N., Hoedemaker R.F., Kranse R. Prostate cancer detection at low prostate specific antigen. J. Urol. 2000, 163:806-812.
13. Antenor J.A., Han M., Roehl K.A., Nadler R.B., Catalona W.J. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J. Urol. 2004, 172:90-93.
14. Botchorishvili G., Matikainen M.P., Lilja H. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr. Opin. Urol. 2009, 19:221-226.
15. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 2008, 8:268-278.
16. Loeb S., Carter H.B., Catalona W.J., Moul J.W., Schroder F.H. Baseline prostate-specific antigen testing at a young age. Eur. Urol. 2012, 61:1-7.
17. Schroder F.H., Hugosson J., Carlsson S., Tammela T., Maattanen L., Auvinen A., Kwiatkowski M., Recker F., Roobol M.J. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer. Eur. Urol. 2012, 62:745-752.
18. Vickers A.J., Ulmert D., Sjoberg D.D., Bennette C.J., Bjork T., Gerdtsson A., Manjer J., Nilsson P.M., Dahlin A., Bjartell A., Scardino P.T., Lilja H. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013, 346:f2023.
19. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20years?. J. Urol. 2004, 172:1297-1301.
20. Mistry K., Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J. Am. Board Fam. Pract. 2003, 16:95-101.
21. Soletormos G., Semjonow A., Sibley P.E., Lamerz R., Petersen P.H., Albrecht W., Bialk P., Gion M., Junker F., Schmid H.P., Van Poppel H. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin. Chem. 2005, 51:1342-1351.
22. Singh R., Cahill D., Popert R., O'Brien T.S. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. BJU Int. 2003, 92:932-935.
23. Hernandez J., Thompson I.M. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004, 101:894-904.
24. Loeb S., Catalona W.J. Prostate-specific antigen in clinical practice. Cancer Lett. 2007, 249:30-39.
25. Nixon R.G., Brawer M.K. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br. J. Urol. 1997, 79(Suppl. 1):61-67.
26. Vickers A.J., Savage C., O'Brien M.F., Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol. 2009, 27:398-403.
27. Lilja H., Christensson A., Dahlen U., Matikainen M.T., Nilsson O., Pettersson K., Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 1991, 37:1618-1625.
28. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991, 51:222-226.
29. Stenman U.H., Leinonen J., Zhang W.M., Finne P. Prostate-specific antigen. Semin. Cancer Biol. 1999, 9:83-93.
30. Leinonen J., Zhang W.M., Stenman U.H. Complex formation between PSA isoenzymes and protease inhibitors. J. Urol. 1996, 155:1099-1103.
31. Jung K., Brux B., Lein M., Rudolph B., Kristiansen G., Hauptmann S., Schnorr D., Loening S.A., Sinha P. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin. Chem. 2000, 46:47-54.
32. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Wolfert R.L., Marks L.S., Song W., Wheeler T.M., Slawin K.M. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000, 55:41-45.
33. Ornstein D.K., Englert C., Gillespie J.W., Paweletz C.P., Linehan W.M., Emmert-Buck M.R., Petricoin E.F. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. Clin. Cancer Res. 2000, 6:353-356.
34. 1-protease inhibitor in vitro. Prostate 1997, 33:87-96.
35. Zhang W.M., Finne P., Leinonen J., Vesalainen S., Nordling S., Rannikko S., Stenman U.H. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin. Chem. 1998, 44:2471-2479.
36. Zhang W.M., Finne P., Leinonen J., Vesalainen S., Nordling S., Stenman U.H. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin. Chem. 1999, 45:814-821.
37. Zhang W.M., Finne P., Leinonen J., Salo J., Stenman U.H. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000, 56:267-272.
38. Stenman U.H., Finne P., Zhang W.M., Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology 2000, 56:893-898.
39. Allard W.J., Zhou Z., Yeung K.K. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin. Chem. 1998, 44:1216-1223.
40. Lein M., Kwiatkowski M., Semjonow A., Luboldt H.J., Hammerer P., Stephan C., Klevecka V., Taymoorian K., Schnorr D., Recker F., Loening S.A., Jung K. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J. Urol. 2003, 170:1175-1179.
41. Stephan C., Schnorr D., Loening S.A., Jung K. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99. Eur. Urol. 2005, 48:1059-1060.
42. Roddam A.W., Duffy M.J., Hamdy F.C., Ward A.M., Patnick J., Price C.P., Rimmer J., Sturgeon C., White P., Allen N.E. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10ng/ml: systematic review and meta-analysis. Eur. Urol. 2005, 48:386-399.
43. Stenman U.H. Detection of complexes between prostate-specific antigen and protease inhibitors in plasma. Clin. Chem. 2010, 56:1895-1896.
44. Stephan C., Jung K., Lein M., Diamandis E.P. PSA and other tissue kallikreins for prostate cancer detection. Eur. J. Cancer 2007, 43:1918-1926.
45. Catalona W.J., Smith D.S., Wolfert R.L., Wang T.J., Rittenhouse H.G., Ratliff T.L., Nadler R.B. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995, 274:1214-1220.
46. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., deKernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N., Parson R.E., Gasior G.H., Loveland K.G., Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
47. Jung K., Stephan C., Lein M., Henke W., Schnorr D., Brux B., Schürenkämper P., Loening S.A. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin. Chem. 1996, 42:1026-1033.
48. Partin A.W., Catalona W.J., Southwick P.C., Subong E.N., Gasior G.H., Chan D.W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996, 48:55-61.
49. Stephan C., Jung K., Lein M., Henke W., Schnorr D., Brux B., Loening S. Freies prostataspezifisches Antigen im Serum: eine Meßgröße zur Diskrimination zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie. J. Lab. Med. 1996, 20:7-12.
50. Stephan C., Jung K., Lein M., Sinha P., Schnorr D., Loening S.A. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2000, 9:1133-1147.
51. Catalona W.J., Partin A.W., Finlay J.A., Chan D.W., Rittenhouse H.G., Wolfert R.L., Woodrum D.L. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999, 54:220-224.
52. Jung K., Stephan C., Elgeti U., Lein M., Brux B., Kristiansen G., Rudolph B., Hauptmann S., Schnorr D., Loening S.A. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4μg/l - are they useful tools for early detection and screening of prostate cancer?. Int. J. Cancer 2001, 93:759-765.
53. Roehl K.A., Antenor J.A., Catalona W.J. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0ng./ml. range. J. Urol. 2002, 168:922-925.
54. Lee R., Localio A.R., Armstrong K., Malkowicz S.B., Schwartz J.S. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006, 67:762-768.
55. Stephan C., Lein M., Jung K., Schnorr D., Loening S.A. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997, 79:104-109.
56. Stephan C., Lein M., Jung K., Schnorr D., Loening S.A. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?[Letter]. J. Urol. 1997, 157:1371.
57. Lee C.T., Scardino P.T. Percent free prostate-specific antigen for first-time prostate biopsy. Urology 2001, 57:594-598.
58. Finne P., Auvinen A., Aro J., Juusela H., Maattanen L., Rannikko S., Hakama M., Tammela T.L., Stenman U.H. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur. Urol. 2002, 41:619-626.
59. Finne P., Auvinen A., Maattanen L., Tammela T.L., Ruutu M., Juusela H., Martikainen P., Hakama M., Stenman U.H. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0microg per liter. Eur. Urol. 2008, 54:362-370.
60. Larsen S.B., Brasso K., Iversen P., Christensen J., Christiansen M., Carlsson S., Lilja H., Friis S., Tjonneland A., Dalton S.O. Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. Eur. J. Cancer 2013, 49:3041-3048.
61. Lilja H., Ulmert D., Bjork T., Becker C., Serio A.M., Nilsson J.A., Abrahamsson P.A., Vickers A.J., Berglund G. Long-term prediction of prostate cancer up to 25years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50years. J. Clin. Oncol. 2007, 25:431-436.
62. Benchikh A., Savage C., Cronin A., Salama G., Villers A., Lilja H., Vickers A. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010, 10:635.
63. Vickers A., Cronin A., Roobol M., Savage C., Peltola M., Pettersson K., Scardino P.T., Schroder F., Lilja H. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J. Clin. Oncol. 2010, 28:2493-2498.
64. Stephan C., Cammann H., Meyer H.A., Lein M., Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett. 2007, 249:18-29.
65. Babaian R.J., Fritsche H., Ayala A., Bhadkamkar V., Johnston D.A., Naccarato W., Zhang Z. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0ng/mL. Urology 2000, 56:1000-1006.
66. Carlson G.D., Calvanese C.B., Partin A.W. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998, 52:455-461.
67. Finne P., Finne R., Auvinen A., Juusela H., Aro J., Maattanen L., Hakama M., Rannikko S., Tammela T.L., Stenman U. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000, 56:418-422.
68. Finne P., Finne R., Bangma C., Hugosson J., Hakama M., Auvinen A., Stenman U.H. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int. J. Cancer 2004, 111:310-315.
69. Horninger W., Bartsch G., Snow P.B., Brandt J.M., Partin A.W. The problem of cutoff levels in a screened population. Cancer 2001, 91:1667-1672.
70. Remzi M., Anagnostou T., Ravery V., Zlotta A., Stephan C., Marberger M., Djavan B. An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 2003, 62:456-460.
71. Stephan C., Cammann H., Semjonow A., Diamandis E.P., Wymenga L.F.A., Lein M., Sinha P., Loening S.A., Jung K. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin. Chem. 2002, 48:1279-1287.
72. Virtanen A., Gomari M., Kranse R., Stenman U.H. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin. Chem. 1999, 45:987-994.
73. Stephan C., Cammann H., Meyer H.A., Muller C., Deger S., Lein M., Jung K. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int. 2008, 102:799-805.
74. Karakiewicz P.I., Benayoun S., Kattan M.W., Perrotte P., Valiquette L., Scardino P.T., Cagiannos I., Heinzer H., Tanguay S., Aprikian A.G., Huland H., Graefen M. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J. Urol. 2005, 173:1930-1934.
75. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Marks L.S., Song W., Wheeler T.M., Slawin K.M. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000, 60:756-759.
76. Mikolajczyk S.D., Marker K.M., Millar L.S., Kumar A., Saedi M.S., Payne J.K., Evans C.L., Gasior C.L., Linton H.J., Carpenter P., Rittenhouse H.G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 61:6958-6963.
77. Nurmikko P., Vaisanen V., Piironen T., Lindgren S., Lilja H., Pettersson K. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin. Chem. 2000, 46:1610-1618.
78. Nurmikko P., Pettersson K., Piironen T., Hugosson J., Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin. Chem. 2001, 47:1415-1423.
79. Peter J., Unverzagt C., Krogh T.N., Vorm O., Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res. 2001, 61:957-962.
80. Mikolajczyk S.D., Marks L.S., Partin A.W., Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 2002, 59:797-802.
81. Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., Mikolajczyk S.D. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin. Chem. 2003, 49:253-259.
82. Stephan C., Cammann H., Deger S., Schrader M., Meyer H.A., Miller K., Lein M., Jung K. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology 2009, 74:873-877.
83. Steuber T., Nurmikko P., Haese A., Pettersson K., Graefen M., Hammerer P., Huland H., Lilja H. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J. Urol. 2002, 168:1917-1922.
84. Mikolajczyk S.D., Catalona W.J., Evans C.L., Linton H.J., Millar L.S., Marker K.M., Katir D., Amirkhan A., Rittenhouse H.G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin. Chem. 2004, 50:1017-1025.
85. Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Amirkhan A., Horninger W., Klocker H., Mikolajczyk S.D. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4ng/ml. J. Urol. 2003, 170:2181-2185.
86. Catalona W.J., Partin A.W., Sanda M.G., Wei J.T., Klee G.G., Bangma C.H., Slawin K.M., Marks L.S., Loeb S., Broyles D.L., Shin S.S., Cruz A.B., Chan D.W., Sokoll L.J., Roberts W.L., van Schaik R.H., Mizrahi I.A. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0ng/ml prostate specific antigen range. J. Urol. 2011, 185:1650-1655.
87. Sokoll L.J., Wang Y., Feng Z., Kagan J., Partin A.W., Sanda M.G., Thompson I.M., Chan D.W. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J. Urol. 2008, 180:539-543.
88. Stephan C., Kahrs A.M., Cammann H., Lein M., Schrader M., Deger S., Miller K., Jung K. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009, 69:198-207.
89. Stephan C., Vincendeau S., Houlgatte A., Cammann H., Jung K., Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin. Chem. 2013, 59:306-314.
90. Jansen F.H., van Schaik R.H., Kurstjens J., Horninger W., Klocker H., Bektic J., Wildhagen M.F., Roobol M.J., Bangma C.H., Bartsch G. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur. Urol. 2010, 57:921-927.
91. Le B.V., Griffin C.R., Loeb S., Carvalhal G.F., Kan D., Baumann N.A., Catalona W.J. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J. Urol. 2010, 183:1355-1359.
92. Lazzeri M., Haese A., de la Taille A., Palou R.J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le C.P., Alberola B.J., Esquena F.S., Graefen M., Guazzoni G. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10ng/ml: a multicentric European study. Eur. Urol. 2013, 63:986-994.
93. Sokoll L.J., Sanda M.G., Feng Z., Kagan J., Mizrahi I.A., Broyles D.L., Partin A.W., Srivastava S., Thompson I.M., Wei J.T., Zhang Z., Chan D.W. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 2010, 19:1193-1200.
94. Hori S., Blanchet J.S., McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 2013, 112:717-728.
95. Heijnsdijk E., Huang J., Denham D., De Koning H.J. The cost-effectiveness of prostate cancer detection using the prostate health index phi. Eur. Urol. Suppl. 2012, 11:e260.
96. Filella X., Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin. Chem. Lab. Med. 2013, 51:729-739.
97. Guazzoni G., Lazzeri M., Nava L., Lughezzani G., Larcher A., Scattoni V., Gadda G.M., Bini V., Cestari A., Buffi N.M., Freschi M., Rigatti P., Montorsi F. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur. Urol. 2012, 61:455-466.
98. Ferro M., Bruzzese D., Perdona S., Mazzarella C., Marino A., Sorrentino A., Di Carlo A., Autorino R., Di Lorenzo G., Buonerba C., Altieri V., Mariano A., Macchia V., Terracciano D. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin. Chim. Acta 2012, 413:1274-1278.
99. Roobol M.J., Carlsson S.V. Risk stratification in prostate cancer screening. Nat. Rev. Urol. 2013, 10:38-48.
100. Loeb S. Prostate Health Index (PHI): golden bullet or just another prostate cancer marker?. Eur. Urol. 2013, 63:995-996.
101. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., Partin A.W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci. 1998, 35:275-368.
102. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 2001, 22:184-204.
103. Lundwall A., Band V., Blaber M., Clements J.A., Courty Y., Diamandis E.P., Fritz H., Lilja H., Malm J., Maltais L.J., Olsson A.Y., Petraki C., Scorilas A., Sotiropoulou G., Stenman U.H., Stephan C., Talieri M., Yousef G.M. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 2006, 387:637-641.
104. Kumar A., Mikolajczyk S.D., Goel A.S., Millar L.S., Saedi M.S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997, 57:3111-3114.
105. Lövgren J., Rajakoski K., Karp M., Lundwall A., Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 1997, 238:549-555.
106. Takayama T.K., Fujikawa K., Davie E.W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 1997, 272:21582-21588.
107. Becker C., Piironen T., Pettersson K., Björk T., Wojno K.J., Oesterling J.E., Lilja H. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J. Urol. 2000, 163:311-316.
108. Kwiatkowski M.K., Recker F., Piironen T., Pettersson K., Otto T., Wernli M., Tscholl R. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10ng/mL. Urology 1998, 52:360-365.
109. Magklara A., Scorilas A., Catalona W.J., Diamandis E.P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin. Chem. 1999, 45:1960-1966.
110. Nam R.K., Diamandis E.P., Toi A., Trachtenberg J., Magklara A., Scorilas A., Papnastasiou P.A., Jewett M.A., Narod S.A. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J. Clin. Oncol. 2000, 18:1036-1042.
111. Partin A.W., Catalona W.J., Finlay J.A., Darte C., Tindall D.J., Young C.Y., Klee G.G., Chan D.W., Rittenhouse H.G., Wolfert R.L., Woodrum D.L. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999, 54:839-845.
112. Haese A., Noldus J., Graefen M., Steuber T., Huland H., Becker C., Lilja H. Human glandular kallikrein 2 (hK2) is superior to total PSA in predicting organ-confined disease and pathological stage of clinically localized prostate cancer with a total PSA <10ng/ml. J. Urol. 2001, 165:234. (Suppl.).
113. Haese A., Graefen M., Steuber T., Becker C., Pettersson K., Piironen T., Noldus J., Huland H., Lilja H. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10ng/ml. Prostate 2001, 49:101-109.
114. Recker F., Kwiatkowski M.K., Piironen T., Pettersson K., Huber A., Lümmen G., Tscholl R. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 2000, 55:481-485.
115. Stephan C., Jung K., Nakamura T., Yousef G.M., Kristiansen G., Diamandis E.P. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int. J. Urol. 2006, 13:238-243.
116. Bangma C.H., Wildhagen M.F., Yurdakul G., Schroder F.H., Blijenberg B.G. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int. 2004, 93:720-724.
117. Haese A., Graefen M., Becker C., Noldus J., Katz J., Cagiannos I., Kattan M., Scardino P.T., Huland E., Huland H., Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003, 54:181-186.
118. Stephan C., Jung K., Soosaipillai A., Yousef G.M., Cammann H., Meyer H., Xu C., Diamandis E.P. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int. 2005, 96:521-527.
119. Takayama T.K., McMullen B.A., Nelson P.S., Matsumura M., Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001, 40:15341-15348.
120. Nakamura T., Scorilas A., Stephan C., Jung K., Soosaipillai A.R., Diamandis E.P. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res. 2003, 63:6543-6546.
121. Stephan C., Meyer H.A., Cammann H., Nakamura T., Diamandis E.P., Jung K. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol. Chem. 2006, 387:801-805.
122. Planque C., Li L., Zheng Y., Soosaipillai A., Reckamp K., Chia D., Diamandis E.P., Goodglick L. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin. Cancer Res. 2008, 14:1355-1362.
123. Ewan K.L., Li X., Cheikh Saad B.K., Pedneault M., Chu C.W. Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin. Biochem. 2007, 40:1057-1062.
124. Stephan C., Yousef G.M., Scorilas A., Jung K., Jung M., Kristiansen G., Hauptmann S., Bharaj B.S., Nakamura T., Loening S.A., Diamandis E.P. Quantitative analysis of kallikrein 15 (KLK15) gene expression in prostate tissue. J. Urol. 2003, 169:361-364.
125. Mavridis K., Stravodimos K., Scorilas A. Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression. Prostate 2013, 73:1191-1201.
126. Rabien A., Fritzsche F.R., Jung M., Tolle A., Diamandis E.P., Miller K., Jung K., Kristiansen G., Stephan C. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int. J. Cancer 2010, 127:2386-2394.
127. Shaw J.L., Grass L., Sotiropoulou G., Diamandis E.P. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin. Biochem. 2007, 40:104-110.
128. Paliouras M., Diamandis E.P. The kallikrein world: an update on the human tissue kallikreins. Biol. Chem. 2006, 387:643-652.
129. Thorek D.L., Evans M.J., Carlsson S.V., Ulmert D., Lilja H. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb. Haemost. 2013, 110:484-492.
130. Stephan C., Rittenhouse H., Cammann H., Lein M., Schrader M., Deger S., Miller K., Jung K. New markers and multivariate models for prostate cancer detection. Anticancer Res. 2009, 29:2589-2600.
131. Diamandis E.P. EPCA-2: a highly specific serum marker for prostate cancer. Clin. Biochem. 2012, 45:600.
132. Brown D.A., Stephan C., Ward R.L., Law M., Hunter M., Bauskin A.R., Amin J., Jung K., Diamandis E.P., Hampton G.M., Russell P.J., Giles G.G., Breit S.N. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin. Cancer Res. 2006, 12:89-96.
133. Brown D.A., Lindmark F., Stattin P., Balter K., Adami H.O., Zheng S.L., Xu J., Isaacs W.B., Gronberg H., Breit S.N., Wiklund F.E. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin. Cancer Res. 2009, 15:6658-6664.
134. Meyer-Siegler K.L., Bellino M.A., Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 2002, 94:1449-1456.
135. Michael A., Stephan C., Kristiansen G., Burckhardt M., Loening S.A., Schnorr D., Jung K. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation. Prostate 2005, 62:34-39.
136. Stephan C., Xu C., Brown D.A., Breit S.N., Michael A., Nakamura T., Diamandis E.P., Meyer H., Cammann H., Jung K. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate 2006, 66:651-659.
137. Hermani A., Hess J., De Servi B., Medunjanin S., Grobholz R., Trojan L., Angel P., Mayer D. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 2005, 11:5146-5152.
138. Ludwig S., Stephan C., Lein M., Loening S.A., Jung K. S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study. Prostate 2007, 67:1301-1307.
139. Lucarelli G., Rutigliano M., Bettocchi C., Palazzo S., Vavallo A., Galleggiante V., Trabucco S., Di Clemente D., Selvaggi F.P., Battaglia M., Ditonno P. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. J. Urol. 2013, 190:2271-2277.
140. Balan V., Wang Y., Nangia-Makker P., Kho D., Bajaj M., Smith D., Heilbrun L., Raz A., Heath E. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget 2013, 4:542-549.
141. Qian X., Li C., Pang B., Xue M., Wang J., Zhou J. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS One 2012, 7:e37225.
142. Barbieri C.E. Evolution of novel biomarkers for detection of prostate cancer. J. Urol. 2013, 190:1970-1971.
143. Koutros S., Meyer T.E., Fox S.D., Issaq H.J., Veenstra T.D., Huang W.Y., Yu K., Albanes D., Chu L.W., Andriole G., Hoover R.N., Hsing A.W., Berndt S.I. Prospective evaluation of serum sarcosine and risk of prostate cancer in the prostate, lung, colorectal and ovarian cancer screening trial. Carcinogenesis 2013, 34:2281-2285.
144. de Vogel S., Ulvik A., Meyer K., Ueland P.M., Nygard O., Vollset S.E., Tell G.S., Gregory J.F., Tretli S., Bjorge T. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer-a large nested case-control study within the JANUS cohort in Norway. Int. J. Cancer 2014, 134:197-206.
145. Struys E.A., Heijboer A.C., van Moorselaar J., Jakobs C., Blankenstein M.A. Serum sarcosine is not a marker for prostate cancer. Ann. Clin. Biochem. 2010, 47:282.
146. Lucarelli G., Ditonno P., Bettocchi C., Spilotros M., Rutigliano M., Vavallo A., Galleggiante V., Fanelli M., Larocca A.M., Germinario C.A., Maiorano E., Selvaggi F.P., Battaglia M. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2013, 9:899-907.
147. Lucarelli G., Fanelli M., Larocca A.M., Germinario C.A., Rutigliano M., Vavallo A., Selvaggi F.P., Bettocchi C., Battaglia M., Ditonno P. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0ng/ml. Prostate 2012, 72:1611-1621.
148. Bohm L., Serafin A.M., Fernandez P., Van der Watt G., Bouic P.J., Harvey J. Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. S. Afr. Med. J. 2012, 102:677-679.
149. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
150. Jentzmik F., Stephan C., Miller K., Schrader M., Erbersdobler A., Kristiansen G., Lein M., Jung K. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol. 2010, 58:12-18.
151. Jentzmik F., Stephan C., Lein M., Miller K., Kamlage B., Bethan B., Kristiansen G., Jung K. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J. Urol. 2011, 185:706-711.
152. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., Swinkels D.W., Schalken J.A. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002, 62:2695-2698.
153. Sokoll L.J., Ellis W., Lange P., Noteboom J., Elliott D.J., Deras I.L., Blase A., Koo S., Sarno M., Rittenhouse H., Groskopf J., Vessella R.L. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin. Chim. Acta 2008, 389:1-6.
154. Cernei N., Heger Z., Gumulec J., Zitka O., Masarik M., Babula P., Eckschlager T., Stiborova M., Kizek R., Adam V. Sarcosine as a potential prostate cancer biomarker-a review. Int. J. Mol. Sci. 2013, 14:13893-13908.
155. Hessels D., Klein Gunnewiek J.M., van Oort I., Karthaus H.F., van Leenders G.J., van Balken B., Kiemeney L.A., Witjes J.A., Schalken J.A. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44:8-15.
156. Filella X., Foj L., Mila M., Auge J.M., Molina R., Jimenez W. PCA3 in the detection and management of early prostate cancer. Tumour Biol. 2013, 34:1337-1347.
157. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., Brentano S., Mathis J., Pham J., Meyer T., Cass M., Hodge P., Macairan M.L., Marks L.S., Rittenhouse H. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 2006, 52:1089-1095.
158. Haese A., de la Taille A., Van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Abbou C.C., Remzi M., Tinzl M., Feyerabend S., Stillebroer A.B., van Gils M.P., Schalken J.A. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur. Urol. 2008, 54:1081-1088.
159. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., Ellis W.J., Marks L.S., Fradet Y., Rittenhouse H., Groskopf J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 2008, 179:1587-1592.
160. Roobol M.J., Schroder F.H., van Leenders G.L., Hessels D., van den Bergh R.C., Wolters T., van Leeuwen P.J. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (>/=100. Eur. Urol. 2010, 58:893-899.
161. Bradley L.A., Palomaki G.E., Gutman S., Samson D., Aronson N. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J. Urol. 2013, 190:389-398.
162. Roobol M.J. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr. Opin. Urol. 2011, 21:225-229.
163. Truong M., Yang B., Jarrard D.F. Toward the detection of prostate cancer in urine: a critical analysis. J. Urol. 2013, 189:422-429.
164. Auprich M., Bjartell A., Chun F.K., de la Taille A., Freedland S.J., Haese A., Schalken J., Stenzl A., Tombal B., van der Poel H. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur. Urol. 2011, 60:1045-1054.
165. Ferro M., Bruzzese D., Perdona S., Marino A., Mazzarella C., Perruolo G., D'Esposito V., Cosimato V., Buonerba C., Di Lorenzo G., Musi G., De Cobelli O., Chun F.K., Terracciano D. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10ng/ml. PLoS One 2013, 8:e67687.
166. Auprich M., Haese A., Walz J., Pummer K., de la Taille A., Graefen M., de Reijke T., Fisch M., Kil P., Gontero P., Irani J., Chun F.K. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur. Urol. 2010, 58:727-732.
167. Hessels D., van Gils M.P., van Hooij O., Jannink S.A., Witjes J.A., Verhaegh G.W., Schalken J.A. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010, 70:10-16.
168. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M., Cancio A.T., Desaulniers M., Ellis W.J., Rittenhouse H., Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69:532-535.
169. Ankerst D.P., Groskopf J., Day J.R., Blase A., Rittenhouse H., Pollock B.H., Tangen C., Parekh D., Leach R.J., Thompson I. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J. Urol. 2008, 180:1303-1308.
170. Aubin S.M., Reid J., Sarno M.J., Blase A., Aussie J., Rittenhouse H., Rittmaster R.S., Andriole G.L., Groskopf J. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology 2011, 78:380-385.
171. Bollito E., De Luca S., Cicilano M., Passera R., Grande S., Maccagnano C., Cappia S., Milillo A., Montorsi F., Scarpa R.M., Papotti M., Randone D.F. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy. Anal. Quant. Cytol. Histol. 2012, 34:96-104.
172. Chun F.K., de la Taille A., Van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Abbou C.C., Stillebroer A.B., van Gils M.P., Schalken J.A., Fradet Y., Marks L.S., Ellis W., Partin A.W., Haese A. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur. Urol. 2009, 56:659-668.
173. Gittelman M.C., Hertzman B., Bailen J., Williams T., Koziol I., Henderson R.J., Efros M., Bidair M., Ward J.F. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J. Urol. 2013, 190:64-69.
174. Hansen J., Auprich M., Ahyai S.A., de la Taille A., Van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Fisch M., Abbou C.C., Schalken J.A., Fradet Y., Marks L.S., Ellis W., Partin A.W., Pummer K., Graefen M., Haese A., Walz J., Briganti A., Shariat S.F., Chun F.K. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur. Urol. 2013, 63:201-209.
175. Ochiai A., Okihara K., Kamoi K., Oikawa T., Shimazui T., Murayama S., Tomita K., Umekawa T., Uemura H., Miki T. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 2013, 111:928-933.
176. Perdona S., Cavadas V., Di Lorenzo G., Damiano R., Chiappetta G., Del Prete P., Franco R., Azzarito G., Scala S., Arra C., De Sio M., Autorino R. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur. Urol. 2011, 59:81-87.
177. Roobol M.J., Schroder F.H., van Leeuwen P., Wolters T., van den Bergh R.C., van Leenders G.J., Hessels D. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur. Urol. 2010, 58:475-481.
178. Stephan C., Jung K., Semjonow A., Schulze-Forster K., Cammann H., Hu X., Meyer H.A., Bogemann M., Miller K., Friedersdorff F. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin. Chem. 2013, 59:280-288.
179. Tombal B., Andriole G.L., de la Taille A., Gontero P., Haese A., Remzi M., Speakman M., Smets L., Stoevelaar H. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?. Urology 2013, 81:998-1004.
180. Goode R.R., Marshall S.J., Duff M., Chevli E., Chevli K.K. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 2013, 73:48-53.
181. Ploussard G., Haese A., Van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Bastien L., Abbou C.C., Remzi M., Tinzl M., Feyerabend S., Stillebroer A.B., van Gils M.P., Schalken J.A., de la Taille A. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. BJU Int. 2010, 106:1143-1147.
182. Aubin S.M., Reid J., Sarno M.J., Blase A., Aussie J., Rittenhouse H., Rittmaster R., Andriole G.L., Groskopf J. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J. Urol. 2010, 184:1947-1952.
183. de la Taille A., Irani J., Graefen M., Chun F., de Reijke T., Kil P., Gontero P., Mottaz A., Haese A. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J. Urol. 2011, 185:2119-2125.
184. Ruffion A., Devonec M., Champetier D., Decaussin-Petrucci M., Rodriguez-Lafrasse C., Paparel P., Perrin P., Vlaeminck-Guillem V. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int. J. Mol. Sci. 2013, 14:17767-17780.
185. Scattoni V., Lazzeri M., Lughezzani G., De Luca S., Passera R., Bollito E., Randone D., Abdollah F., Capitanio U., Larcher A., Lista G., Gadda G.M., Bini V., Montorsi F., Guazzoni G. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J. Urol. 2013, 190:496-501.
186. Crawford E.D., Rove K.O., Trabulsi E.J., Qian J., Drewnowska K.P., Kaminetsky J.C., Huisman T.K., Bilowus M.L., Freedman S.J., Glover W.L., Bostwick D.G. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1962 cases. J. Urol. 2012, 188:1726-1731.
187. Vlaeminck-Guillem V., Bandel M., Cottancin M., Rodriguez-Lafrasse C., Bohbot J.M., Sednaoui P. Chronic prostatitis does not influence urinary PCA3 score. Prostate 2012, 72:549-554.
188. Leyten G.H., Wierenga E.A., Sedelaar J.P., van Oort I.M., Futterer J.J., Barentsz J.O., Schalken J.A., Mulders P.F. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int. J. Mol. Sci. 2013, 14:11347-11355.
189. Perdona S., Bruzzese D., Ferro M., Autorino R., Marino A., Mazzarella C., Perruolo G., Longo M., Spinelli R., Di Lorenzo G., Oliva A., De Sio M., Damiano R., Altieri V., Terracciano D. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013, 73:227-235.
190. Salagierski M., Schalken J.A. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J. Urol. 2012, 187:795-801.
191. Barbieri C.E., Bangma C.H., Bjartell A., Catto J.W., Culig Z., Gronberg H., Luo J., Visakorpi T., Rubin M.A. The mutational landscape of prostate cancer. Eur. Urol. 2013, 64:567-576.
192. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
193. Esgueva R., Perner S., LaFargue J., Scheble V., Stephan C., Lein M., Fritzsche F.R., Dietel M., Kristiansen G., Rubin M.A. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod. Pathol. 2010, 23:539-546.
194. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., Tchinda J., Tomlins S.A., Hofer M.D., Pienta K.G., Kuefer R., Vessella R., Sun X.W., Meyerson M., Lee C., Sellers W.R., Chinnaiyan A.M., Rubin M.A. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006, 66:8337-8341.
195. Groskopf J., Siddiqui J., Aubin S.M.J., Sefton-Miller L., Day J., Blase A., Varambally S., Schalken J., Sakamoto K., Fradet Y., Rittenhouse H., Chinnaiyan A. Feasibility and clinical utility of a TMPRSS2:ERG gene fusion urine test [Abstract]. Eur. Urol. Suppl. 2009, 8:195.
196. Young A., Palanisamy N., Siddiqui J., Wood D.P., Wei J.T., Chinnaiyan A.M., Kunju L.P., Tomlins S.A. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am. J. Clin. Pathol. 2012, 138:685-696.
197. Salami S.S., Schmidt F., Laxman B., Regan M.M., Rickman D.S., Scherr D., Bueti G., Siddiqui J., Tomlins S.A., Wei J.T., Chinnaiyan A.M., Rubin M.A., Sanda M.G. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. 2013, 31:566-571.
198. Cornu J.N., Cancel-Tassin G., Egrot C., Gaffory C., Haab F., Cussenot O. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 2013, 73:242-249.
199. Leyten G.H., Hessels D., Jannink S.A., Smit F.P., de Jong H., Cornel E.B., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C., van Oort I.M., Mulders P.F., Hulsbergen-van de Kaa C.A., Schalken J.A. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 2014, 65:534-542.
200. Tomlins S.A., Aubin S.M., Siddiqui J., Lonigro R.J., Sefton-Miller L., Miick S., Williamsen S., Hodge P., Meinke J., Blase A., Penabella Y., Day J.R., Varambally R., Han B., Wood D., Wang L., Sanda M.G., Rubin M.A., Rhodes D.R., Hollenbeck B., Sakamoto K., Silberstein J.L., Fradet Y., Amberson J.B., Meyers S., Palanisamy N., Rittenhouse H., Wei J.T., Groskopf J., Chinnaiyan A.M. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 2011, 3:94ra72.
201. Dimitriadis E., Kalogeropoulos T., Velaeti S., Sotiriou S., Vassiliou E., Fasoulis L., Klapsas V., Synesiou M., Apostolaki A., Trangas T., Pandis N. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res. 2013, 33:191-197.
202. Robert G., Jannink S., Smit F., Aalders T., Hessels D., Cremers R., Mulders P.F., Schalken J.A. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate 2013, 73:113-120.
203. Rigau M., Ortega I., Mir M.C., Ballesteros C., Garcia M., Llaurado M., Colas E., Pedrola N., Montes M., Sequeiros T., Ertekin T., Majem B., Planas J., Ruiz A., Abal M., Sanchez A., Morote J., Reventos J., Doll A. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 2011, 71:1736-1745.
204. Cao D.L., Ye D.W., Zhang H.L., Zhu Y., Wang Y.X., Yao X.D. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 2011, 71:700-710.
205. Katafigiotis I., Tyritzis S.I., Stravodimos K.G., Alamanis C., Pavlakis K., Vlahou A., Makridakis M., Katafigioti A., Garbis S.D., Constantinides C.A. Zinc alpha2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int. 2012, 110:E688-E693.
206. Jamaspishvili T., Kral M., Khomeriki I., Student V., Kolar Z., Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010, 13:12-19.
207. Roobol M.J., Haese A., Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol. 2011, 50(Suppl. 1):85-89.
208. Hessels D., Schalken J.A. Urinary biomarkers for prostate cancer: a review. Asian J. Androl. 2013, 15:333-339.